PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27997874-4 2017 PATIENTS AND METHODS: Formalin-fixed paraffin embedded archival tumour tissue samples from four phase II studies of temozolomide or dacarbazine in MGMT MSP-positive mCRCs were analysed by IHC for MGMT protein expression and by methyl-BEAMing (MB) for percentage of promoter methylation. Dacarbazine 132-143 O-6-methylguanine-DNA methyltransferase Homo sapiens 147-151 26916096-1 2016 BACKGROUND: Objective response to dacarbazine, the intravenous form of temozolomide (TMZ), in metastatic colorectal cancer (mCRC) is confined to tumors harboring O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter hypermethylation. Dacarbazine 34-45 O-6-methylguanine-DNA methyltransferase Homo sapiens 162-202 26916096-1 2016 BACKGROUND: Objective response to dacarbazine, the intravenous form of temozolomide (TMZ), in metastatic colorectal cancer (mCRC) is confined to tumors harboring O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter hypermethylation. Dacarbazine 34-45 O-6-methylguanine-DNA methyltransferase Homo sapiens 204-208 25400033-1 2015 To investigate the predictive and prognostic value of O(6) -methylguanine DNA methyltransferase (MGMT) inactivation by analyses of promoter methylation in pretreatment tumor biopsies from patients with cutaneous melanoma treated with dacarbazine (DTIC) or temozolomide (TMZ) were performed. Dacarbazine 234-245 O-6-methylguanine-DNA methyltransferase Homo sapiens 54-95 26113646-1 2015 BACKGROUND: O(6)-methyl-guanine-methyl-transferase (MGMT) silencing by promoter methylation may identify cancer patients responding to the alkylating agents dacarbazine or temozolomide. Dacarbazine 157-168 O-6-methylguanine-DNA methyltransferase Homo sapiens 12-50 26113646-1 2015 BACKGROUND: O(6)-methyl-guanine-methyl-transferase (MGMT) silencing by promoter methylation may identify cancer patients responding to the alkylating agents dacarbazine or temozolomide. Dacarbazine 157-168 O-6-methylguanine-DNA methyltransferase Homo sapiens 52-56 26113646-6 2015 Cutoff values of MGMT methylation specific for metastatic colorectal cancer (mCRC) tissue samples were established in a cohort of 60 patients treated with dacarbazine. Dacarbazine 155-166 O-6-methylguanine-DNA methyltransferase Homo sapiens 17-21 26113646-9 2015 In mCRC patients treated with dacarbazine, exploratory analysis of cfDNA by methyl-BEAMing showed that MGMT methylation was associated with better response and improved median PFS (P = 0.008). Dacarbazine 30-41 O-6-methylguanine-DNA methyltransferase Homo sapiens 103-107 25400033-1 2015 To investigate the predictive and prognostic value of O(6) -methylguanine DNA methyltransferase (MGMT) inactivation by analyses of promoter methylation in pretreatment tumor biopsies from patients with cutaneous melanoma treated with dacarbazine (DTIC) or temozolomide (TMZ) were performed. Dacarbazine 234-245 O-6-methylguanine-DNA methyltransferase Homo sapiens 97-101 25400033-1 2015 To investigate the predictive and prognostic value of O(6) -methylguanine DNA methyltransferase (MGMT) inactivation by analyses of promoter methylation in pretreatment tumor biopsies from patients with cutaneous melanoma treated with dacarbazine (DTIC) or temozolomide (TMZ) were performed. Dacarbazine 247-251 O-6-methylguanine-DNA methyltransferase Homo sapiens 54-95 25400033-1 2015 To investigate the predictive and prognostic value of O(6) -methylguanine DNA methyltransferase (MGMT) inactivation by analyses of promoter methylation in pretreatment tumor biopsies from patients with cutaneous melanoma treated with dacarbazine (DTIC) or temozolomide (TMZ) were performed. Dacarbazine 247-251 O-6-methylguanine-DNA methyltransferase Homo sapiens 97-101 25400033-10 2015 DTIC/TMZ therapy response rate was found to be significantly associated with MGMT promoter methylation in cohort S (p = 0.0005), but did not reach significance in cohort C (p = 0.16). Dacarbazine 0-4 O-6-methylguanine-DNA methyltransferase Homo sapiens 77-81 25400033-13 2015 Together, this implies that MGMT promoter methylation is associated with response to single-agent DTIC/TMZ and longer PFS in disseminated cutaneous melanoma. Dacarbazine 98-102 O-6-methylguanine-DNA methyltransferase Homo sapiens 28-32 25516857-2 2014 Its prognostic role has not been defined yet, but loss of expression of MGMT, which is secondary to gene promoter methylation, results in an interesting high response to alkylating agents such as dacarbazine and temozolomide. Dacarbazine 196-207 O-6-methylguanine-DNA methyltransferase Homo sapiens 72-76 25584486-8 2015 Progression-free survival and OS from first alkylant use (temozolomide, dacarbazine and streptozotocin) were higher in patients with MGMT protein loss (respectively, 20.2 vs 7.6 months, P<0.001 and 105 vs 34 months, P=0.006) or MGMT promoter methylation assessed by pyrosequencing (respectively, 26.4 vs 10.8 months, P=0.002 and 77 vs 43 months, P=0.026). Dacarbazine 72-83 O-6-methylguanine-DNA methyltransferase Homo sapiens 133-137 23422094-0 2013 Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. Dacarbazine 97-108 O-6-methylguanine-DNA methyltransferase Homo sapiens 62-66 24284332-0 2014 Impact of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine resistance of Hodgkin"s lymphoma cells. Dacarbazine 100-111 O-6-methylguanine-DNA methyltransferase Homo sapiens 10-48 24284332-0 2014 Impact of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine resistance of Hodgkin"s lymphoma cells. Dacarbazine 100-111 O-6-methylguanine-DNA methyltransferase Homo sapiens 81-85 24284332-2 2014 Expression of MGMT correlated with the presence of non-methylated promoters and cell lines with non-methylated promoters showed increased resistance against dacarbazine. Dacarbazine 157-168 O-6-methylguanine-DNA methyltransferase Homo sapiens 14-18 24284332-5 2014 MGMT promoter methylation predicts dacarbazine sensitivity of HL cells and it might be interesting to analyze this factor in HL patients. Dacarbazine 35-46 O-6-methylguanine-DNA methyltransferase Homo sapiens 0-4 23422094-3 2013 Alkylating agents, such as dacarbazine, exert their antitumor activity by DNA methylation at the O(6)-guanine site, inducing base pair mismatch; therefore, activity of dacarbazine could be enhanced in CRCs lacking MGMT. Dacarbazine 27-38 O-6-methylguanine-DNA methyltransferase Homo sapiens 214-218 23422094-3 2013 Alkylating agents, such as dacarbazine, exert their antitumor activity by DNA methylation at the O(6)-guanine site, inducing base pair mismatch; therefore, activity of dacarbazine could be enhanced in CRCs lacking MGMT. Dacarbazine 168-179 O-6-methylguanine-DNA methyltransferase Homo sapiens 214-218 23422094-14 2013 CONCLUSION: Objective clinical responses to dacarbazine in patients with metastatic CRC are confined to those tumors harboring epigenetic inactivation of the DNA repair enzyme MGMT. Dacarbazine 44-55 O-6-methylguanine-DNA methyltransferase Homo sapiens 176-180 17881774-5 2007 A mismatch recognition complex, composed of MSH2, MSH6, MLH1, PMS2 and PCNA, is formed after exposing MGMT-deficient cells to dacarbazine, but not in cells treated with ACNU. Dacarbazine 126-137 O-6-methylguanine-DNA methyltransferase Homo sapiens 102-106 21811257-1 2011 BACKGROUND: The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) reverses the O6-methylguanine (O6-meG) lesion induced by dacarbazine. Dacarbazine 138-149 O-6-methylguanine-DNA methyltransferase Homo sapiens 35-73 21811257-1 2011 BACKGROUND: The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) reverses the O6-methylguanine (O6-meG) lesion induced by dacarbazine. Dacarbazine 138-149 O-6-methylguanine-DNA methyltransferase Homo sapiens 75-79 20541396-0 2010 MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. Dacarbazine 141-145 O-6-methylguanine-DNA methyltransferase Homo sapiens 0-4 20541396-2 2010 We report the results of a prospective single institution study evaluating O(6)-methylguanine-DNA methyltransferase (MGMT) status as a potential predictive and/or prognostic marker among patients treated with dacarbazine (DTIC) 800-1000 mg/m(2) monotherapy administered as a 3-weekly schedule for advanced malignant melanomas. Dacarbazine 209-220 O-6-methylguanine-DNA methyltransferase Homo sapiens 75-115 20541396-2 2010 We report the results of a prospective single institution study evaluating O(6)-methylguanine-DNA methyltransferase (MGMT) status as a potential predictive and/or prognostic marker among patients treated with dacarbazine (DTIC) 800-1000 mg/m(2) monotherapy administered as a 3-weekly schedule for advanced malignant melanomas. Dacarbazine 209-220 O-6-methylguanine-DNA methyltransferase Homo sapiens 117-121 20541396-2 2010 We report the results of a prospective single institution study evaluating O(6)-methylguanine-DNA methyltransferase (MGMT) status as a potential predictive and/or prognostic marker among patients treated with dacarbazine (DTIC) 800-1000 mg/m(2) monotherapy administered as a 3-weekly schedule for advanced malignant melanomas. Dacarbazine 222-226 O-6-methylguanine-DNA methyltransferase Homo sapiens 75-115 20541396-2 2010 We report the results of a prospective single institution study evaluating O(6)-methylguanine-DNA methyltransferase (MGMT) status as a potential predictive and/or prognostic marker among patients treated with dacarbazine (DTIC) 800-1000 mg/m(2) monotherapy administered as a 3-weekly schedule for advanced malignant melanomas. Dacarbazine 222-226 O-6-methylguanine-DNA methyltransferase Homo sapiens 117-121 20541396-10 2010 Our data reveal MGMT expression levels to be associated with disease stabilisation and prognosis in patients receiving DTIC monotherapy for advanced melanoma. Dacarbazine 119-123 O-6-methylguanine-DNA methyltransferase Homo sapiens 16-20 17881774-3 2007 Human cells deficient in both MGMT and MLH1 are resistant to the killing effect of dacarbazine and exhibit an increased mutant frequency after treatment with dacarbazine. Dacarbazine 83-94 O-6-methylguanine-DNA methyltransferase Homo sapiens 30-34 17881774-3 2007 Human cells deficient in both MGMT and MLH1 are resistant to the killing effect of dacarbazine and exhibit an increased mutant frequency after treatment with dacarbazine. Dacarbazine 158-169 O-6-methylguanine-DNA methyltransferase Homo sapiens 30-34 19741564-1 2009 OBJECTIVES: The efficacy of temozolomide (TMZ) or dacarbazine (DTIC) in melanoma treatment depends on low O-6-methylguanine-DNA-methyltransferase (MGMT) repair and on high mismatch repair. Dacarbazine 50-61 O-6-methylguanine-DNA methyltransferase Homo sapiens 106-145 19741564-1 2009 OBJECTIVES: The efficacy of temozolomide (TMZ) or dacarbazine (DTIC) in melanoma treatment depends on low O-6-methylguanine-DNA-methyltransferase (MGMT) repair and on high mismatch repair. Dacarbazine 50-61 O-6-methylguanine-DNA methyltransferase Homo sapiens 147-151 19741564-1 2009 OBJECTIVES: The efficacy of temozolomide (TMZ) or dacarbazine (DTIC) in melanoma treatment depends on low O-6-methylguanine-DNA-methyltransferase (MGMT) repair and on high mismatch repair. Dacarbazine 63-67 O-6-methylguanine-DNA methyltransferase Homo sapiens 106-145 19741564-1 2009 OBJECTIVES: The efficacy of temozolomide (TMZ) or dacarbazine (DTIC) in melanoma treatment depends on low O-6-methylguanine-DNA-methyltransferase (MGMT) repair and on high mismatch repair. Dacarbazine 63-67 O-6-methylguanine-DNA methyltransferase Homo sapiens 147-151 19741564-10 2009 CONCLUSION: Our results indicate that either low or high host expression of MGMT, MLH1, and MSH2 may serve as a marker for reduced hematologic side effects of TMZ or DTIC, but not for treatment efficacy in melanoma. Dacarbazine 166-170 O-6-methylguanine-DNA methyltransferase Homo sapiens 76-80 16278661-1 2005 Tumour resistance to chemotherapy involving methylating agents such as DTIC (dacarbazine) and temozolomide is linked to expression of the DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (MGMT). Dacarbazine 71-75 O-6-methylguanine-DNA methyltransferase Homo sapiens 197-201 16278661-1 2005 Tumour resistance to chemotherapy involving methylating agents such as DTIC (dacarbazine) and temozolomide is linked to expression of the DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (MGMT). Dacarbazine 77-88 O-6-methylguanine-DNA methyltransferase Homo sapiens 197-201 15010317-5 2004 Mgmt-deficient cells are hypersensitive to the killing action of dacarbazine. Dacarbazine 65-76 O-6-methylguanine-DNA methyltransferase Homo sapiens 0-4 15870882-1 2005 The aim of this study was to assess whether combined evaluation of O6-methylguanine methyltransferase (MGMT) and hMLH1 status determines sensitivity to monofuntional alkylating agents such as N-methyl-N-nitrosourea (MNU) and dacarbazine (DTIC) against gallbladder carcinoma cells. Dacarbazine 225-236 O-6-methylguanine-DNA methyltransferase Homo sapiens 67-101 15870882-1 2005 The aim of this study was to assess whether combined evaluation of O6-methylguanine methyltransferase (MGMT) and hMLH1 status determines sensitivity to monofuntional alkylating agents such as N-methyl-N-nitrosourea (MNU) and dacarbazine (DTIC) against gallbladder carcinoma cells. Dacarbazine 225-236 O-6-methylguanine-DNA methyltransferase Homo sapiens 103-107 15870882-1 2005 The aim of this study was to assess whether combined evaluation of O6-methylguanine methyltransferase (MGMT) and hMLH1 status determines sensitivity to monofuntional alkylating agents such as N-methyl-N-nitrosourea (MNU) and dacarbazine (DTIC) against gallbladder carcinoma cells. Dacarbazine 238-242 O-6-methylguanine-DNA methyltransferase Homo sapiens 67-101 15870882-1 2005 The aim of this study was to assess whether combined evaluation of O6-methylguanine methyltransferase (MGMT) and hMLH1 status determines sensitivity to monofuntional alkylating agents such as N-methyl-N-nitrosourea (MNU) and dacarbazine (DTIC) against gallbladder carcinoma cells. Dacarbazine 238-242 O-6-methylguanine-DNA methyltransferase Homo sapiens 103-107 15870882-8 2005 The highest sensitivity to DTIC was also observed in MGMT-/hMLH1+. Dacarbazine 27-31 O-6-methylguanine-DNA methyltransferase Homo sapiens 53-57 15010317-6 2004 On the other hand, cells defective in both Mgmt and Mlh1 genes are as resistant to the drug as are wild-type cells, in terms of survival, but do have many mutations after dacarbazine treatment. Dacarbazine 171-182 O-6-methylguanine-DNA methyltransferase Homo sapiens 43-47 14562026-1 2003 In a retrospective study, O(6)-methylguanine-DNA-methyltransferase (MGMT) expression was analysed by immunohistochemistry using monoclonal human anti-MGMT antibody in melanoma metastases in patients receiving dacarbazine (DTIC) as single-drug therapy or as part of combination chemotherapy with DTIC-vindesine or DTIC-vindesine-cisplatin. Dacarbazine 209-220 O-6-methylguanine-DNA methyltransferase Homo sapiens 26-66 14562026-1 2003 In a retrospective study, O(6)-methylguanine-DNA-methyltransferase (MGMT) expression was analysed by immunohistochemistry using monoclonal human anti-MGMT antibody in melanoma metastases in patients receiving dacarbazine (DTIC) as single-drug therapy or as part of combination chemotherapy with DTIC-vindesine or DTIC-vindesine-cisplatin. Dacarbazine 209-220 O-6-methylguanine-DNA methyltransferase Homo sapiens 68-72 14562026-1 2003 In a retrospective study, O(6)-methylguanine-DNA-methyltransferase (MGMT) expression was analysed by immunohistochemistry using monoclonal human anti-MGMT antibody in melanoma metastases in patients receiving dacarbazine (DTIC) as single-drug therapy or as part of combination chemotherapy with DTIC-vindesine or DTIC-vindesine-cisplatin. Dacarbazine 222-226 O-6-methylguanine-DNA methyltransferase Homo sapiens 26-66 14562026-1 2003 In a retrospective study, O(6)-methylguanine-DNA-methyltransferase (MGMT) expression was analysed by immunohistochemistry using monoclonal human anti-MGMT antibody in melanoma metastases in patients receiving dacarbazine (DTIC) as single-drug therapy or as part of combination chemotherapy with DTIC-vindesine or DTIC-vindesine-cisplatin. Dacarbazine 222-226 O-6-methylguanine-DNA methyltransferase Homo sapiens 68-72 14562026-3 2003 There was an inverse relationship between MGMT expression and clinical response to DTIC-based chemotherapy (P=0.05). Dacarbazine 83-87 O-6-methylguanine-DNA methyltransferase Homo sapiens 42-46 12168066-0 2002 Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy. Dacarbazine 162-166 O-6-methylguanine-DNA methyltransferase Homo sapiens 64-102 10751609-2 2000 Expression of low or high levels of a transfected human MGMT gene under the control of the metallothionein promoter protected the cells against dacarbazine-induced toxicity and mutagenesis. Dacarbazine 144-155 O-6-methylguanine-DNA methyltransferase Homo sapiens 56-60 12170182-0 2002 Analysis of O(6)-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy. Dacarbazine 98-109 O-6-methylguanine-DNA methyltransferase Homo sapiens 12-52 12170182-1 2002 In a retrospective study we analysed the levels of the DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT) in melanoma metastases in patients receiving dacarbazine (DTIC) either as a single drug or as part of combination chemotherapy regimens, and related the expression levels to the clinical response to treatment. Dacarbazine 167-178 O-6-methylguanine-DNA methyltransferase Homo sapiens 74-114 12170182-1 2002 In a retrospective study we analysed the levels of the DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT) in melanoma metastases in patients receiving dacarbazine (DTIC) either as a single drug or as part of combination chemotherapy regimens, and related the expression levels to the clinical response to treatment. Dacarbazine 167-178 O-6-methylguanine-DNA methyltransferase Homo sapiens 116-120 12170182-1 2002 In a retrospective study we analysed the levels of the DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT) in melanoma metastases in patients receiving dacarbazine (DTIC) either as a single drug or as part of combination chemotherapy regimens, and related the expression levels to the clinical response to treatment. Dacarbazine 180-184 O-6-methylguanine-DNA methyltransferase Homo sapiens 74-114 12170182-1 2002 In a retrospective study we analysed the levels of the DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT) in melanoma metastases in patients receiving dacarbazine (DTIC) either as a single drug or as part of combination chemotherapy regimens, and related the expression levels to the clinical response to treatment. Dacarbazine 180-184 O-6-methylguanine-DNA methyltransferase Homo sapiens 116-120 12170182-9 2002 These data are consistent with the hypothesis that MGMT contributes to resistance to DTIC-based treatment, although the difference between responders and non-responders with respect to the proportion of MGMT-positive tumour cells was not statistically significant (P = 0.077). Dacarbazine 85-89 O-6-methylguanine-DNA methyltransferase Homo sapiens 51-55 9038616-2 1996 Tumour cells which lack MGMT are sensitive to cytostatic drugs such as dacarbazine (DTIC), whose active species bind to this site. Dacarbazine 71-82 O-6-methylguanine-DNA methyltransferase Homo sapiens 24-28 9071912-7 1997 Tumour cells with moderate to strong immunostaining with MGMT antiserum were significantly more abundant in metastases excised after dacarbazine-based chemotherapy (n = 8) than in those excised before treatment (n = 29). Dacarbazine 133-144 O-6-methylguanine-DNA methyltransferase Homo sapiens 57-61 9038616-2 1996 Tumour cells which lack MGMT are sensitive to cytostatic drugs such as dacarbazine (DTIC), whose active species bind to this site. Dacarbazine 84-88 O-6-methylguanine-DNA methyltransferase Homo sapiens 24-28 33816296-0 2021 LncRNA POU3F3 Contributes to Dacarbazine Resistance of Human Melanoma Through the MiR-650/MGMT Axis. Dacarbazine 29-40 O-6-methylguanine-DNA methyltransferase Homo sapiens 90-94 8645346-1 1996 O6-Methylguanine-DNA methyltransferase (MGMT) is an important DNA repair protein that plays a key role in cancer chemotherapy by alkylating agents such as carmustine (BCNU) and Dacarbazine (DTIC). Dacarbazine 177-188 O-6-methylguanine-DNA methyltransferase Homo sapiens 0-38 8645346-1 1996 O6-Methylguanine-DNA methyltransferase (MGMT) is an important DNA repair protein that plays a key role in cancer chemotherapy by alkylating agents such as carmustine (BCNU) and Dacarbazine (DTIC). Dacarbazine 177-188 O-6-methylguanine-DNA methyltransferase Homo sapiens 40-44 8645346-1 1996 O6-Methylguanine-DNA methyltransferase (MGMT) is an important DNA repair protein that plays a key role in cancer chemotherapy by alkylating agents such as carmustine (BCNU) and Dacarbazine (DTIC). Dacarbazine 190-194 O-6-methylguanine-DNA methyltransferase Homo sapiens 0-38 8645346-1 1996 O6-Methylguanine-DNA methyltransferase (MGMT) is an important DNA repair protein that plays a key role in cancer chemotherapy by alkylating agents such as carmustine (BCNU) and Dacarbazine (DTIC). Dacarbazine 190-194 O-6-methylguanine-DNA methyltransferase Homo sapiens 40-44 8645346-2 1996 Therapy by BCNU and DTIC is reduced by dose-limiting hematological toxicity as a result of low MGMT repair activity in bone marrow cells. Dacarbazine 20-24 O-6-methylguanine-DNA methyltransferase Homo sapiens 95-99 33816296-11 2021 Conclusion: LncRNA POU3F3 upregulated the expression of MGMT by sponging miR-650, which is a crucial way for DTIC resistance in melanoma. Dacarbazine 109-113 O-6-methylguanine-DNA methyltransferase Homo sapiens 56-60